Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare wi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/9/2255 |
| _version_ | 1797505383955169280 |
|---|---|
| author | Marilina García-Aranda Teresa Téllez Lauraine McKenna Maximino Redondo |
| author_facet | Marilina García-Aranda Teresa Téllez Lauraine McKenna Maximino Redondo |
| author_sort | Marilina García-Aranda |
| collection | DOAJ |
| description | Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance. |
| first_indexed | 2024-03-10T04:17:52Z |
| format | Article |
| id | doaj.art-3e514d26c4424f09a084d60e6aea86d9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:17:52Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3e514d26c4424f09a084d60e6aea86d92023-11-23T07:57:02ZengMDPI AGCancers2072-66942022-04-01149225510.3390/cancers14092255Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer ResistanceMarilina García-Aranda0Teresa Téllez1Lauraine McKenna2Maximino Redondo3Research and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, SpainRed de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC) and Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, SpainResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, SpainResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, SpainNowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.https://www.mdpi.com/2072-6694/14/9/2255cancertachykinintachykinin receptorNK-1Rtargeted treatmentdrug repurposing |
| spellingShingle | Marilina García-Aranda Teresa Téllez Lauraine McKenna Maximino Redondo Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance Cancers cancer tachykinin tachykinin receptor NK-1R targeted treatment drug repurposing |
| title | Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance |
| title_full | Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance |
| title_fullStr | Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance |
| title_full_unstemmed | Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance |
| title_short | Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance |
| title_sort | neurokinin 1 receptor nk 1r antagonists as a new strategy to overcome cancer resistance |
| topic | cancer tachykinin tachykinin receptor NK-1R targeted treatment drug repurposing |
| url | https://www.mdpi.com/2072-6694/14/9/2255 |
| work_keys_str_mv | AT marilinagarciaaranda neurokinin1receptornk1rantagonistsasanewstrategytoovercomecancerresistance AT teresatellez neurokinin1receptornk1rantagonistsasanewstrategytoovercomecancerresistance AT laurainemckenna neurokinin1receptornk1rantagonistsasanewstrategytoovercomecancerresistance AT maximinoredondo neurokinin1receptornk1rantagonistsasanewstrategytoovercomecancerresistance |